

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicants:	Hiroyuki Kishino, et al.		Art Unit:
Serial No.:	10/567,269	Case No.: BY0030P	1614
Filed:	February 6, 2006		Examiner:
For:	IMIDAZOPYRIDINE DERIVATIVES		Niloofar Rahmani

Commissioner of Patents and Trademarks  
P.O. Box 1450  
Alexandria, VA, 22313-1450

INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR § 1.97

Sir:

In compliance with 37 CFR § 1.97, Applicants and other individuals associated with the filing or prosecution of this application wish to bring to the attention of the Examiner the patents, publications, and other information of which they are aware, listed on the attached form PTO/SB/08a, which they believe may be relevant to the examination of this application or may be material to patentability and in respect of which there may be a duty to disclose in accordance with 37 CFR § 1.56. Applicants respectfully request that the Examiner initial the form PTO/SB/08a after reviewing the pertinence of each reference.


The Information Disclosure Statement is not an admission that any patent, publication, or other information referred to herein is "prior art" for this invention.

In accordance with 37 CFR § 1.97(h), the filing of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the Statement is, or is considered to be, material to patentability as defined in 37 CFR § 1.56(b). In accordance with 37 CFR § 1.97(g), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made.

Any additional fees required in connection with this submission may be taken from Merck Deposit Account No. 13-2755.

Serial No.: 10/567,269  
Case No.: BY0030P  
Page 2

Respectfully submitted,

By   
Janet E. Fair  
Reg. No. 56,042  
Attorney for Applicant

MERCK & CO., INC.  
P.O. Box 2000  
Rahway, New Jersey 07065-0907  
(732) 594-6819

Date: October 9, 2008